Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 2336 Download: 179 Web of Science: 2 Crossref: 2

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, Ana Clemente-Sánchez, Hugo López-Pelayo, Ramón Bataller

Clin Mol Hepatol. 2025;31(Suppl):S112-S133. Published online October 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0709

View: 2884 Download: 294 Web of Science: 3 Crossref: 4

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4765 Download: 349 Web of Science: 9 Crossref: 11

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6601 Download: 247 Web of Science: 4 Crossref: 5

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1676 Download: 192 Web of Science: 2 Crossref: 5

Research Letter

Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease

Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul

Clin Mol Hepatol. 2025;31(3):e273-e276. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0474

View: 395 Download: 16

Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e268-e272. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384

View: 515 Download: 34

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility

Dongyao Wang, Hongwei Zhang, Yuxiao Tang

Clin Mol Hepatol. 2025;31(3):e259-e262. Published online April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0227

View: 737 Download: 60 Crossref: 1

Letter to the Editor

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai

Clin Mol Hepatol. 2025;31(3):e247-e248. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0073

View: 723 Download: 37

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

View: 886 Download: 68

Original Article

Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study

Xianhua Mao, Xinrong Zhang, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(3):1084-1099. Published online April 23, 2025

DOI: https://doi.org/10.3350/cmh.2024.1096

View: 1575 Download: 164

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States

Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(3):1058-1070. Published online April 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0169

View: 1696 Download: 99

High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease

Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao

Clin Mol Hepatol. 2025;31(3):796-809. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.0822

View: 1845 Download: 195

Correspondence

Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”

Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0166

View: 1257 Download: 32

Editorial

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 1531 Download: 75 Web of Science: 1 Crossref: 1

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1854 Download: 66 Web of Science: 2 Crossref: 3

Original Article

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 4829 Download: 329 Web of Science: 8 Crossref: 11

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 3930 Download: 485 Web of Science: 11 Crossref: 16

Correspondence

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 1199 Download: 32

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815

View: 1368 Download: 30

Letter to the Editor

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 1140 Download: 44 Web of Science: 1 Crossref: 1

Editorial

The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2025;31(1):316-318. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0847

View: 1282 Download: 58

Original Article

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S117-S133. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0392

View: 3569 Download: 170 Web of Science: 5 Crossref: 6

Reply to Correspondence

Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):1047-1049. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0666

View: 1623 Download: 58

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 2059 Download: 63 Crossref: 1

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2024;30(4):989-991. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0705

View: 1450 Download: 50 Crossref: 1

Letter to the Editor

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233

View: 1981 Download: 75 Web of Science: 5 Crossref: 5

Original Article

The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study

Keungmo Yang, Sunghwan Kim, Hyun Yang, Sheng-Min Wang, Bumseok Jeong, Hyun Kook Lim, Si Hyun Bae

Clin Mol Hepatol. 2024;30(4):929-942. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0278

View: 2842 Download: 141 Crossref: 1

Editorial

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Junjie Yu

Clin Mol Hepatol. 2024;30(4):721-723. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443

View: 1831 Download: 66 Web of Science: 1

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 2415 Download: 71 Web of Science: 3 Crossref: 3

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |

Viewed By 12318	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7544	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 6974	MAFLD: How is it different from NAFLD?
Viewed By 5610	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5436	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 348	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search